{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:10:03Z","timestamp":1748650203967,"version":"3.41.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.annder.2025.103367","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:55:26Z","timestamp":1745326526000},"page":"103367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bullous pemphigoid following radiotherapy combined with ipilimumab-nivolumab therapy"],"prefix":"10.1016","volume":"152","author":[{"given":"A.","family":"Pankakoski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Panelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"158","key":"10.1016\/j.annder.2025.103367_b0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"1","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103367_b0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2006.11.014","article-title":"Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect","volume":"82","author":"Mul","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annder.2025.103367_b0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lpm.2016.09.019","article-title":"Bullous pemphigoid triggered by radiotherapy for breast cancer","volume":"46","author":"Kluger","year":"2017","journal-title":"Presse Med"},{"key":"10.1016\/j.annder.2025.103367_b0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ced.13309","article-title":"Dabrafenib-induced pemphigoid-like reaction","volume":"43","author":"Satta","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2025.103367_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000487127","article-title":"Intensity-modulated radiotherapy triggers onset of bullous pemphigoid in a patient with advanced melanoma treated with Nivolumab","volume":"11","author":"Tanita","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.annder.2025.103367_b0030","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1111\/ajd.12987","article-title":"Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect","volume":"60","author":"Grimaux","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2025.103367_b0035","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028199","article-title":"Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: a case report of abscopal toxicities","volume":"100","author":"Huynh","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.annder.2025.103367_b0040","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103367_b0045","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T23:36:18Z","timestamp":1748648178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963825000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0151963825000262"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103367","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bullous pemphigoid following radiotherapy combined with ipilimumab-nivolumab therapy","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103367"}}